Company intelligence / Profile preview

AIM ImmunoTech

Ocala, Florida, United Statesaimimmuno.com ↗

Ownership: Public · AIM
Development stage: Phase 2

Overview

AIM ImmunoTech’s lead program Ampligen® has shown broad-spectrum activity as an immune modulator. It has demonstrated positive preliminary data in pancreatic cancer trials and favorable results in a Phase 2 study of post-COVID fatigue. The company continues to expand its pipeline with ongoing or planned studies in various solid tumors and viral diseases. Several programs are supported by partnerships with major pharma companies like AstraZeneca and Merck as well as the National Cancer Institute. Ampligen® is approved for severe CFS in Argentina.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: RNA-based drugs (e.g., double-stranded RNA)immunomodulatorsnatural interferon
Industry: Biotech

Drug pipeline

3 assets

interferon alfa-n3

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca (for Imfinzi combination studies)MerckNational Cancer Institute funding support for certain trialsAmarex Clinical Research as CRO partner for clinical trial management

Beyond the preview

Go deeper on AIM ImmunoTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIM ImmunoTech.

Explore the full profile